Autologous mesenchymal stem cell intrathecal therapy for multiple system atrophy

Lire cet article en français

Takeaway

  • Intrathecal administration of mesenchymal stem cells (MSCs) for treatment of multiple system atrophy (MSA) is adequately safe and well tolerated.

Why this matters

  • This study provides class 4 evidence that intrathecal MSCs are safe in MSA and informs the design of future placebo-controlled efficacy trials.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.